Angiotensin 1-7 inhibits angiotensin II-stimulated head and neck cancer progression

2017 ◽  
Vol 125 (4) ◽  
pp. 247-257 ◽  
Author(s):  
E. E. Hinsley ◽  
C. E. de Oliveira ◽  
S. Hunt ◽  
R. D. Coletta ◽  
D. W. Lambert
Keyword(s):  
Head And Neck Cancer ◽  
Angiotensin Ii ◽  
Head And Neck ◽  
Cancer Progression ◽  
Neck Cancer

scholarly journals The Development and Treatment of Lymphatic Dysfunction in Cancer Patients and Survivors

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2280
Author(s):  
Melissa B. Aldrich ◽  
John C. Rasmussen ◽  
Caroline E. Fife ◽  
Simona F. Shaitelman ◽  
Eva M. Sevick-Muraca
Keyword(s):  
Breast Cancer ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Neck Cancer ◽  
Cancer Metastasis ◽  
Near Infrared ◽  
Critical Role ◽  
Lymphatic Function

Breast-cancer-acquired lymphedema is routinely diagnosed from the appearance of irreversible swelling that occurs as a result of lymphatic dysfunction. Yet in head and neck cancer survivors, lymphatic dysfunction may not always result in clinically overt swelling, but instead contribute to debilitating functional outcomes. In this review, we describe how cancer metastasis, lymph node dissection, and radiation therapy alter lymphatic function, as visualized by near-infrared fluorescence lymphatic imaging. Using custom gallium arsenide (GaAs)-intensified systems capable of detecting trace amounts of indocyanine green administered repeatedly as lymphatic contrast for longitudinal clinical imaging, we show that lymphatic dysfunction occurs with cancer progression and treatment and is an early, sub-clinical indicator of cancer-acquired lymphedema. We show that early treatment of lymphedema can restore lymphatic function in breast cancer and head and neck cancer patients and survivors. The compilation of these studies provides insights to the critical role that the lymphatics and the immune system play in the etiology of lymphedema and associated co-morbidities.

scholarly journals Serumal and Salivary 25(OH)D and 1,25(OH)D Levels of Head and Neck Cancer Patients

2021 ◽  
Vol 13 (4) ◽  
pp. 438-43
Author(s):  
Dina Keumala Sari ◽  
Liza Meutia Sari ◽  
Lidya Imelda Laksmi ◽  
Farhat Farhat ◽  
Elvita Rahmi Daulay ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Progression ◽  
Neck Cancer ◽  
Medical Records ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Exclusion Criteria ◽  
Dihydroxyvitamin D ◽  
Saliva Collection

BACKGROUND: Saliva has been suggested as a substitute of serum for the detection of 25 Dihydroxyvitamin D (25(OH)D) in healthy people. However, investigation of salivary 1,25(OH)D has not been clearly reported. Vitamin plays important roles in inhibiting cancer progression. Current study was conducted to investigate serumal and salivary 25(OH)D) and 1,25(OH)D levels of healthy and head and neck cancer (HNC) subjects.METHODS: Research were conducted at Haji Adam Malik Hospital, Medan, Indonesia. Forty HNC and 40 healthy subjects were recruited and selected based on inclusion and exclusion criteria. Medical records were documented, followed by anthropometric evaluation and serum and saliva collection. Laboratory investigation for 25(OH)D and 1,25(OH) was performed using Enzyme-linked immunosorbent assay (ELISA) methods.RESULTS: Significant serumal (p=0.002) and salivary (p=0.016) 25(OH)D mean level differences of HNC and normal groups were obtained. More serumal or salivary 25(OH)D deficient subjects were found in control group than those in HNC group. Meanwhile, serumal and salivary 1,25(OH)D mean levels of HNC group were not significantly different with the ones of control group. There were significant correlations of serumal-salivary 25(OH)D as well as serumal-salivary 1,25(OH)D levels in normal group.CONCLUSION: Serumal and salivary 25(OH)D and 1,25(OH)D levels of HNC group were relatively normal. Salivary 25(OH)D and 1,25(OH)D could be suggested as substitutes for serumal ones.KEYWORDS: vitamin D, 25(OH)D, 1,25(OH)D, head and neck cancer

A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer

2019 ◽  
Vol 98 (5) ◽  
pp. 489-497 ◽  
Author(s):  
P.J. Polverini ◽  
M.W. Lingen
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Progression ◽  
Neck Cancer ◽  
New Technologies ◽  
Treatment Strategies ◽  
Disease Process ◽  
Treatment Protocols ◽  
Multistep Process ◽  
Etiological Agents

Historical records as far back as 3000 BCE show that oral and head and neck cancer was a disease process well known to Egyptian physicians. Luminaries such as Hippocrates, Galen, Pott, and Virchow were instrumental in shaping our understanding of the etiology and pathogenesis of cancer. During the 20th century, evidence-based medicine catalyzed the development of rigorous science-based diagnostic and treatment protocols. The use of surgery, therapeutic radiation, and chemotherapy as single-treatment agents or in combination with one another gradually emerged as the preferred approach to cancer therapy. The recognition of tobacco, alcohol, and human papillomavirus as etiological agents in oral and head and neck cancer prompted the development of new diagnostic aids and treatment strategies to mitigate cancer progression. More in-depth mechanistic insights into the multistep process of oral and head and neck cancer were made possible by the use of the hamster buccal pouch and mouse models. New technologies, such as the sequencing of the human genome, metabolomics, and proteomics, have provided the foundation for what we today call precision medicine. The future success of tailored medical treatment for cancer patients will depend on the discovery of new druggable targets with improved therapeutic efficacy. As the precision and sensitivity of existing tools for prevention and risk assessment improve, greater accuracy will be achieved in predicting health outcomes.

scholarly journals Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2935
Author(s):  
Hui Li ◽  
Hoi-Lam Ngan ◽  
Yuchen Liu ◽  
Helen Hoi Yin Chan ◽  
Peony Hiu Yan Poon ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Progression ◽  
Neck Cancer ◽  
Pi3k Pathway ◽  
Kras Mutations ◽  
Cancer Hallmarks ◽  
Genome Analyses ◽  
Immune Defects

Immunocompetent metastatic head and neck cancer (HNC) models, although scarce, can help understanding cancer progression and therapy responses in vivo. Their comprehensive genome characterizations are essential for translational research. We first exome-sequenced the two most widely used spontaneous metastatic immunocompetent models, namely AT-84 and SCC VII, followed by comprehensive genomic analyses with three prior-sequenced models (MOC2, MOC2-10, and 4MOSC2), together with patient tumors for utility assessment. AT-84 and SCC VII bear high HNC tumor resemblance regarding mutational signatures—Trp53, Fanconi anemia, and MAPK and PI3K pathway defects. Collectively, the five models harbor genetic aberrations across 10 cancer hallmarks and 14 signaling pathways and machineries (metabolic, epigenetic, immune evasion), to extents similar in patients. Immune defects in HLA-A (H2-Q10, H2-Q4, H2-Q7, and H2-K1), Pdcd1, Tgfb1, Il2ra, Il12a, Cd40, and Tnfrsf14 are identified. Invasion/metastatic genome analyses first highlight potential druggable ERBB4 and KRAS mutations, for advanced/metastatic oral cavity cancer, as well as known metastasis players (Muc5ac, Trem3, Trp53, and Ttn) frequently captured by all models. Notable immunotherapy and precision druggable targets (Pdcd1, Erbb4, Fgfr1, H/Kras, Jak1, and Map2k2) and three druggable hubs (RTK family, MAPK, and DNA repair pathways) are frequently represented by these models. Immunocompetent metastatic HNC models are worth developing to address therapy- and invasion/metastasis-related questions in host immunity contexts.

scholarly journals Sox11 promotes head and neck cancer progression via the regulation of SDCCAG8

2019 ◽  
Vol 38 (1) ◽  
Author(s):  
Junwei Huang ◽  
Eoon Hye Ji ◽  
Xinyuan Zhao ◽  
Li Cui ◽  
Kaori Misuno ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Progression ◽  
Neck Cancer

scholarly journals IL-10 and integrin signaling pathways are associated with head and neck cancer progression

BMC Genomics ◽  
2016 ◽  
Vol 17 (1) ◽  
Author(s):  
Sophia Bornstein ◽  
Mark Schmidt ◽  
Gabrielle Choonoo ◽  
Trevor Levin ◽  
Joe Gray ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Signaling Pathways ◽  
Cancer Progression ◽  
Neck Cancer ◽  
Integrin Signaling

scholarly journals Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression

2016 ◽  
Vol 18 (1) ◽  
pp. 7 ◽  
Author(s):  
Anne von Mässenhausen ◽  
Johannes Brägelmann ◽  
Hannah Billig ◽  
Britta Thewes ◽  
Angela Queisser ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Tyrosine Kinase ◽  
Head And Neck ◽  
Cancer Progression ◽  
Neck Cancer ◽  
Receptor Tyrosine Kinase
Sign in / Sign up

Export Citation Format

Share Document